Moleculin Biotech Inc (MBRX) — Cash Flow-to-Debt Ratio
Moleculin Biotech Inc (MBRX) has a Cash Flow-to-Debt Ratio of -0.75x as of December 2025, meaning its operating cash flow of $-5.37 Million could theoretically repay -1% of its total liabilities ($7.12 Million) in one year. Check MBRX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Moleculin Biotech Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Moleculin Biotech Inc across 11 annual periods. Also explore how large is Moleculin Biotech Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Moleculin Biotech Inc (2015–2025)
Year-by-year debt coverage analysis for Moleculin Biotech Inc. For market capitalisation and broader financial context, see Moleculin Biotech Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.19x | $-22.73 Million | $7.12 Million | ▼ -46.5% |
| 2024 | -2.18x | $-23.86 Million | $10.95 Million | ▼ -9.8% |
| 2023 | -1.98x | $-24.10 Million | $12.14 Million | ▲ +62.4% |
| 2022 | -5.28x | $-27.64 Million | $5.23 Million | ▼ -42.1% |
| 2021 | -3.72x | $-18.95 Million | $5.10 Million | ▼ -135.8% |
| 2020 | -1.58x | $-17.77 Million | $11.27 Million | ▲ +11.4% |
| 2019 | -1.78x | $-17.20 Million | $9.66 Million | ▲ +22.5% |
| 2018 | -2.30x | $-12.20 Million | $5.31 Million | ▲ +25.8% |
| 2017 | -3.10x | $-7.32 Million | $2.37 Million | ▼ -17.8% |
| 2016 | -2.63x | $-3.76 Million | $1.43 Million | ▼ -379.6% |
| 2015 | -0.55x | $-423.51K | $772.79K | — |